{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-276390","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.986758+00:00","generated_at":"2026-06-22T09:34:50.336255+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AlloVir reports Q3 net loss $42.1M; cash $264.1M, advancing Phase 3 posoleucel trials","bullets":["Net loss of $42.1M ($0.50/sh) in Q3 2022 vs $45.5M ($0.72) in Q3 2021.","Cash & securities $264.1M; raised $126.4M net from registered direct offering July 2022.","R&D expenses $30.0M, G&A $12.9M; FY2022 opex guidance $130M-$145M excl. stock comp.","Phase 3 posoleucel trials ongoing; final Phase 2 multi-virus prevention data by year-end.","Topline Phase 2 BK viremia data in kidney transplant patients expected Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-276390","json":"https://secwatch.observer/filing/0001193125-22-276390.json","markdown":"https://secwatch.observer/filing/0001193125-22-276390.md","text":"https://secwatch.observer/filing/0001193125-22-276390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522276390/0001193125-22-276390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522276390/d408523d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:34:50.336255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69f46270e4d88b72d30d929b9d08335cd960434a","claim":"Kalaris Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, AlloVir, Inc. announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522276390/0001193125-22-276390-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}